Annual EBITDA
-$32.47 M
+$20.24 M+38.40%
31 December 2023
Summary:
Werewolf Therapeutics annual earnings before interest, taxes, depreciation & amortization is currently -$32.47 million, with the most recent change of +$20.24 million (+38.40%) on 31 December 2023. During the last 3 years, it has fallen by -$10.21 million (-45.88%). HOWL annual EBITDA is now -227.57% below its all-time high of -$9.91 million, reached on 31 December 2019.HOWL EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBITDA
-$14.97 M
+$678.00 K+4.33%
30 September 2024
Summary:
Werewolf Therapeutics quarterly earnings before interest, taxes, depreciation & amortization is currently -$14.97 million, with the most recent change of +$678.00 thousand (+4.33%) on 30 September 2024. Over the past year, it has dropped by -$8.14 million (-119.00%). HOWL quarterly EBITDA is now -303.75% below its all-time high of -$3.71 million, reached on 30 June 2023.HOWL Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBITDA
-$55.89 M
-$8.14 M-17.04%
30 September 2024
Summary:
Werewolf Therapeutics TTM earnings before interest, taxes, depreciation & amortization is currently -$55.89 million, with the most recent change of -$8.14 million (-17.04%) on 30 September 2024. Over the past year, it has dropped by -$23.44 million (-72.24%). HOWL TTM EBITDA is now -1343.74% below its all-time high of -$3.87 million, reached on 31 March 2020.HOWL TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
HOWL EBITDA Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +38.4% | -119.0% | -72.2% |
| 3 y3 years | -45.9% | -9.1% | -41.9% |
| 5 y5 years | - | - | - |
HOWL EBITDA High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -45.9% | +38.4% | -303.8% | +16.0% | -72.2% | +9.3% |
| 5 y | 5 years | -227.6% | +38.4% | -303.8% | +16.0% | -1343.7% | +9.3% |
| alltime | all time | -227.6% | +38.4% | -303.8% | +16.0% | -1343.7% | +9.3% |
Werewolf Therapeutics EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$14.97 M(-4.3%) | -$55.89 M(+17.0%) |
| June 2024 | - | -$15.65 M(+6.3%) | -$47.75 M(+33.4%) |
| Mar 2024 | - | -$14.73 M(+39.8%) | -$35.81 M(+10.3%) |
| Dec 2023 | -$32.47 M(-38.4%) | -$10.53 M(+54.0%) | -$32.47 M(+0.1%) |
| Sept 2023 | - | -$6.84 M(+84.4%) | -$32.45 M(-14.0%) |
| June 2023 | - | -$3.71 M(-67.4%) | -$37.74 M(-22.7%) |
| Mar 2023 | - | -$11.38 M(+8.3%) | -$48.82 M(-7.4%) |
| Dec 2022 | -$52.71 M | -$10.52 M(-13.3%) | -$52.71 M(-12.2%) |
| Sept 2022 | - | -$12.13 M(-17.9%) | -$60.03 M(-2.6%) |
| June 2022 | - | -$14.79 M(-3.2%) | -$61.62 M(+6.7%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2022 | - | -$15.27 M(-14.4%) | -$57.73 M(+15.8%) |
| Dec 2021 | -$49.87 M(+124.1%) | -$17.84 M(+29.9%) | -$49.87 M(+26.6%) |
| Sept 2021 | - | -$13.73 M(+26.0%) | -$39.38 M(+24.4%) |
| June 2021 | - | -$10.89 M(+47.0%) | -$31.67 M(+22.8%) |
| Mar 2021 | - | -$7.41 M(+0.9%) | -$25.80 M(+15.9%) |
| Dec 2020 | -$22.25 M(+124.5%) | -$7.35 M(+22.2%) | -$22.25 M(+49.3%) |
| Sept 2020 | - | -$6.01 M(+19.7%) | -$14.91 M(+67.6%) |
| June 2020 | - | -$5.02 M(+29.8%) | -$8.89 M(+129.8%) |
| Mar 2020 | - | -$3.87 M | -$3.87 M |
| Dec 2019 | -$9.91 M | - | - |
FAQ
- What is Werewolf Therapeutics annual earnings before interest, taxes, depreciation & amortization?
- What is the all time high annual EBITDA for Werewolf Therapeutics?
- What is Werewolf Therapeutics annual EBITDA year-on-year change?
- What is Werewolf Therapeutics quarterly earnings before interest, taxes, depreciation & amortization?
- What is the all time high quarterly EBITDA for Werewolf Therapeutics?
- What is Werewolf Therapeutics quarterly EBITDA year-on-year change?
- What is Werewolf Therapeutics TTM earnings before interest, taxes, depreciation & amortization?
- What is the all time high TTM EBITDA for Werewolf Therapeutics?
- What is Werewolf Therapeutics TTM EBITDA year-on-year change?
What is Werewolf Therapeutics annual earnings before interest, taxes, depreciation & amortization?
The current annual EBITDA of HOWL is -$32.47 M
What is the all time high annual EBITDA for Werewolf Therapeutics?
Werewolf Therapeutics all-time high annual earnings before interest, taxes, depreciation & amortization is -$9.91 M
What is Werewolf Therapeutics annual EBITDA year-on-year change?
Over the past year, HOWL annual earnings before interest, taxes, depreciation & amortization has changed by +$20.24 M (+38.40%)
What is Werewolf Therapeutics quarterly earnings before interest, taxes, depreciation & amortization?
The current quarterly EBITDA of HOWL is -$14.97 M
What is the all time high quarterly EBITDA for Werewolf Therapeutics?
Werewolf Therapeutics all-time high quarterly earnings before interest, taxes, depreciation & amortization is -$3.71 M
What is Werewolf Therapeutics quarterly EBITDA year-on-year change?
Over the past year, HOWL quarterly earnings before interest, taxes, depreciation & amortization has changed by -$8.14 M (-119.00%)
What is Werewolf Therapeutics TTM earnings before interest, taxes, depreciation & amortization?
The current TTM EBITDA of HOWL is -$55.89 M
What is the all time high TTM EBITDA for Werewolf Therapeutics?
Werewolf Therapeutics all-time high TTM earnings before interest, taxes, depreciation & amortization is -$3.87 M
What is Werewolf Therapeutics TTM EBITDA year-on-year change?
Over the past year, HOWL TTM earnings before interest, taxes, depreciation & amortization has changed by -$23.44 M (-72.24%)